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Abstract: There is evidence demonstrating that heart failure (HF) occurs in 1–2% of the global
population and is often accompanied by comorbidities which contribute to increasing the prevalence
of the disease, the rate of hospitalization and the mortality. Although recent advances in both
pharmacological and non-pharmacological approaches have led to a significant improvement in
clinical outcomes in patients affected by HF, residual unmet needs remain, mostly related to the
occurrence of poorly defined strategies in the early stages of myocardial dysfunction. Nutritional
support in patients developing HF and nutraceutical supplementation have recently been shown to
possibly contribute to protection of the failing myocardium, although their place in the treatment
of HF requires further assessment, in order to find better therapeutic solutions. In this context, the
Optimal Nutraceutical Supplementation in Heart Failure (ONUS-HF) working group aimed to assess
the optimal nutraceutical approach to HF in the early phases of the disease, in order to counteract
selected pathways that are imbalanced in the failing myocardium. In particular, we reviewed several
of the most relevant pathophysiological and molecular changes occurring during the early stages of
myocardial dysfunction. These include mitochondrial and sarcoplasmic reticulum stress, insufficient
nitric oxide (NO) release, impaired cardiac stem cell mobilization and an imbalanced regulation
of metalloproteinases. Moreover, we reviewed the potential of the nutraceutical supplementation
of several natural products, such as coenzyme Q10 (CoQ10), a grape seed extract, Olea Europea
L.-related antioxidants, a sodium–glucose cotransporter (SGLT2) inhibitor-rich apple extract and
a bergamot polyphenolic fraction, in addition to their support in cardiomyocyte protection, in HF.
Such an approach should contribute to optimising the use of nutraceuticals in HF, and the effect
needs to be confirmed by means of more targeted clinical trials exploring the efficacy and safety of
these compounds.
Keywords: heart failure; dysfunctional cardiomyocytes; patho-physiological mechanisms; oxidative
stress; nutraceuticals
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1. Introduction
Heart failure (HF) represents a multifactorial disease state with a global prevalence of
1–2% in the population [1]. Comorbidities frequently associated with HF are hypertension,
diabetes, and obesity or hyperlipidaemia. These comorbidities thereby increase the preva-
lence of the disease, the rate of hospitalisation, and mortality [2,3]. In addition, ageing
affects the number of patients experiencing HF; the occurrence of the disease rises to 10%
in people aged >70 years [4,5].
According to recent international treatment guidelines, better management of risk
factors and increased pharmacological and non-pharmacological treatment significantly
reduce the impact of HF and its consequences. In particular, recent data from a pilot
study on HF performed by the European Society of Cardiology (ESC) showed that the
all-cause mortality prevalence, at 12 months, was 17% for hospitalised HF patients and
7% for stable/ambulatory HF patients, with hospitalisation rates for the same period
being 44% and 32%, respectively [1]. Hence, several relevant outcomes of HF remain
unsatisfactory and additional studies are required to address the currently unmet needs in
the management of the disease.
Recently, growing evidence has suggested that greater control of the nutritional bal-
ance in patients experiencing HF (with special regards to the micronutrient and nutraceu-
tical supply) leads to a significant improvement in the symptoms and consequences of
the disease [5–7]. On the other hand, the identification of novel biomolecular mechanisms
that lead to the onset of HF, which are only partially counteracted by current treatments,
suggests the potential for an additional contribution in the management of HF via optimal
micronutrient and nutraceutical supplementation [8–12].
There is evidence that the majority of HF patients exhibit an insufficient support
of micronutrients and that such a condition leads to an increased prevalence of the dis-
ease [13–16]. Moreover, conditions of dysfunctional myocardium and impaired muscle
functionality are accompanied by oxidative stress and micronutrient deficiency [13–17].
Finally, there is also evidence that an insufficient micronutrient supply may trigger HF, as
well as impair a pre-existing condition of cardiac dysfunction [13,17].
Additionally, multiple conditions related to micronutrient deficiency can lead to a
depletion of the lean body mass (LBM). A pro-inflammatory state, inadequate intake,
metabolic changes, increased oxidative stress and increased nutrient loss can all contribute
to a loss of LBM. Furthermore, the depletion of LBM can affect vital organs, including the
myocardium, thereby negatively influencing its functional capacity [12–16].
Although preliminary evidence suggests that nutraceutical supplementation could be
beneficial in treating patients undergoing a decaying heart performance, there is limited
evidence supporting its extensive use in patients with HF, as reported in recent studies
and meta-analyses [18,19] (Table 1). The major weaknesses in the existing evidence include
the small number of studies performed and the inconsistent number of study participants,
which is associated with a diminished study quality with a high risk of bias. Considering
this, definite conclusions cannot be drawn. Consequently, it is the general opinion that clin-
icians should presently favour other treatments that have clearly been shown to decrease
mortality [18–20] (Table 2).
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Table 1. Protective effects of nutritional components in clinical trials.
Bioactive
Component Clinical Trials Study Duration Dosage Supplement Properties References
Coenzyme Q10
- Meta-analysis of 13 randomised
controlled trials
- Includes 395 participants (49.8 to
68.0 years)
At baseline:
- Blood CoQ10 concentration
0.61–1.01 µg/mL.
- EF 22–46%.
- NYHA functional class 2.3–3.4
4–28 weeks 60–300 mg/day
- Pooled mean net increase in
blood CoQ10 concentration:
1.4 µg/mL (95% CI: 1.1,
1.7 µg/mL)
- Pooled mean net increase in
EF: 3.67%
(95% CI: 1.60%, 5.74%)
- Study-specific changes in EF
CoQ10 supplementation vs.
placebo: −3.0% (95% CI: −10.7%,
4.7%) to 17.8%
(95% CI: 7.2%, 28.4%)
- Pooled mean net change in
NYHA classification: −0.30
(95% CI: −0.66, 0.06)
[21]
- A randomised controlled
multicenter trial
Q-SYMBIO
- Includes 420 patients with
moderate to severe HF
At baseline:
- Chronic HF in NYHA functional
class III or IV
- Typical symptoms and signs
of HF





- NYHA functional class
and functional status
- VAS for symptoms
- 6MWT
- echocardiography








- VAS for symptoms
- MACE
100 mg 3 times/day
After 16weeks:
- The level of serum
CoQ10-treated group increased to
about 3 times the baseline value
- NT-proBNP reduction
(mean value of 384 pg/mL (20%)
vs. 199 pg/mL (12%)
After 106 weeks:
- Fewer MACE (N = 30, 15% vs.
N = 57, 26%)
- Improved NYHA functional
classification (N = 86, 58% vs.
N = 68, 45%)
- At least 1 grade of improvement
in NYHA functional class
- Reduced serum NT-proBNP
(mean value of 1137 pg/mL;
60% vs. mean value
881 pg/mL; 52%)
- Lower total number of
cardiovascular deaths
(N = 18, 9% vs. N = 34, 16%),
corresponding to a 43%
relative reduction.
- Lower number of hospital stays
for HF (N = 17, 8% vs.
N = 31, 14%)
- Lower number of adverse events
(mean value 26 (13%) vs. 41 (19%)
[22]
BPF
- A randomised, double-blind,
placebo-controlled study
- Includes 237 patients:
group A (104 patients) with
isolated HC
(LDL-C levels ≥130 mg/dL)
group B (42 patients) with
HC/HT
group C (59 patients) with mixed
HC/HT/HG
over 110 mg/dL
group D (32 patients) who
stopped simvastatin therapy
30 consecutive days 500, 1000 or1500 mg/day
- In group A, B and C
reduction in:
- tChol (mean value from
278 mg/mL to 199 mg/mL)
- LDL-C (mean value from
188 mg/mL to 126 mg/mL)
- TG (mean value from
267 mg/mL to 158 mg/mL)
- Increase in HDL-C was observed
with the best response in
the 10% subjects (−64.6%)
- Reduction in blood
glucose levels
(mean value of −18.9% under 500
mg BPF treatment and
−22.4% in 1000 mg
BPF treatment)
- Group D, 30/32 patients
showed a reduction in tChol
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Table 1. Cont.
Bioactive
Component Clinical Trials Study Duration Dosage Supplement Properties References
- A randomised double-blind,
placebo-controlled study
- Includes 60 patients suffering
from T2DM with:
Serum glucose >110 mg/dL))
Mixed hyperlipemia
(LDL-C >120 mg/dL and
TG >175 mg/dL)
30 consecutive days 650 mg BPFtwice/day
- Fasting plasma glucose
(from 120 ± 1.6 mg/mL to
98 ± 1.3 mg/mL)
- tChol (262 ± 14 mg/dL to
196 ± 12 mg/dL)
- LDL-C (175 ± 5.8 mg/mL to
116 ± 3.2 mg/mL)
- HDL-C (44 ± 4.1 mg/mL to
48 + 3.8 mg/mL)
- Triglycerides (252 ± 9 mg/mL
to 170 + 7 mg/mL)
- Relevant changes in mean
particle diameters for
VLDL, LDL, and HDL
- Decrease the mean
concentration of IDL particles to
Increase large LDL and to
decrease small LDL.
- Increase in total HDL particles
[24]
- A prospective, open-label,
parallel group, placebo-
controlled study
- Includes 77 patients mixed
hypercholesterolemia
(LDL-C = 160 mg/dL,




- BPF (1000 mg/day)
- BPF+rosuvastatin
(10 mg/day)
- tChol (mean value from
278 ± 4 mg/dL to
191 ± 5 mg/dL)
- LDL-C (mean value from
191 ± 3 mg/dL to
191 ± 3 mg/dL)
- TG (mean value from
238 ± 5 mg/dL to
165 ± 3 mg/dL)
- HDL-C (mean value from
38 ± 2 mg/dL to 45 ± 4 mg/dL)




- tChol (mean value from
172 ± 3 mg/dL to
195 ± 3 mg/dL)
- LDL-C (mean value from
90 ± 4 mg/dL to
115 ± 4 mg/dL),
- TG (mean value from
152 ± 5 mg/dL to
200 ± 4 mg/dL)
- HDL-C (mean value from
52 ± 4 mg/dL to 42 ± 3 mg/dL)
- Reduced urinary MVA excretion
- Decreased both MDA levels and
LOX-1 expression in
PMNs of patients
- Enhanced phosphorylation of
PKB1 expression in
PMNs of patients







- An open, controlled,
parallel-group, co-twin study
- Including 40 borderline
hypertensive monozygotic
patients (18 and 60 years) with:
an untreated SBP >120 mmHg or
DBP >80 mmHg at rest
8 weeks 500 mg and1000 mg/day
- 1000 mg significantly reduces:
SBP (mean value 126 ± 9 vs.
137 ± 10)
DBP (76 ± 6 vs. 80 ± 10)
- Reduction in LDL-C
[26]
- A double-blind, randomised,
parallel and active-
controlled clinical study
- Includes 232 patients (25 and
60 years)
in stage-1 hypertension
with SBP of 140–159 mmHg,
DBP <90 mmHg
or in between 90 and 99 mmHg
- 4-weeks single-blind
placebo (is diet-alone)




500 mg twice/day vs.
captopril treatment
(12.5 mg twice/day)
- significant reduction in:
SBP (−11.5 ± 8.6 mmHg vs.
−13.7 ± 7.6 mmHg in captopril)
DBP (−4.8 ± 5.5 mmHg vs.
−6.4 ± 5.2 mmHg captopril)
- LDL-C (−3.89 ± 19.40 mg/dL
vs. 2.14 ± 14.20 mg/dL
in captopril)
- TG (−11.90 ± 46.17 mg/dL vs.
−1.26 ± 43.31 mg/dL
in captopril)
[27]
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Table 1. Cont.
Bioactive





- Includes 7020 patients (≥18
years) with T2DM at high risk of
CV disease with:
- BMI ≤ 45 kg/m2;
- No glucose-lowering therapy in
previous 12 weeks
-HbA1c 7.0–9.0%, or stable
glucose-lowering
therapy and HbA1c 7.0–10.0%
- Glomerular filtration rate (eGFR)






10 mg or 25 mg
Primary outcome:
- All-cause mortality: HR 0.68
(95% CI 0.57, 0.82; p < 0.001)
- Incident or worsening
nephropathy: HR 0.61 (95% CI
0.53, 0.70; p < 0.001)
- Lower rates of death from
cardiovascular causes (3.7%, vs.
5.9% in te placebo; 38% relative
risk reduction; HR 0.62
(95% CI 0.49, 0.77; p < 0.001)
- Hospitalization for heart failure
(2.7% and 4.1%,
respectively; 35% relative risk
reduction; HR 0.65 (95%
CI 0.50, 0.85; p = 0.002)
- Death from any cause (5.7% and
8.3%, respectively; 32% relative
risk reduction)
[28]
- Declare-TIMI 58 trial
- includes 17,160 patients
(40 years) with T2DM and risk of













of cardiovascular death or
hospitalization for heart failure
(4.9% vs. 5.8%; HR, 0.83; 95% CI,
0.73 to 0.95; p = 0.005)
- Lower rate of hospitalization for
heart failure (HR, 0.73; 95% CI,
0.61 to 0.88)
kidney composite outcome:
- A renal event occurred in 4.3%
vs. 5.6% in placebo (HR, 0.76;
95% CI, 0.67 to 0.87)
- Death from any cause occurred
in 6.2% and 6.6%, respectively
(HR, 0.93; 95% CI, 0.82 to 1.04)
[29]
BMI: body mass index; BPF: bergamot polyphenolic fraction; CI: Confidence Interval; EF: ejection fraction; DBP: diastolic blood pressure;
HC/HT: hypercholesterolemia and hypertriglyceridemia; HC/HT/HG: hyperlipidemia and glycemia; HDL-C: high density lipoprotein
cholesterol; HF: heart failure; HR: hazard ratio; HC: hypercholesterolemia; LDL-C: low density lipoprotein cholesterol; LOX-1: Lectin-
like oxidised low-density lipoprotein (LDL) receptor-1; MACE: major adverse cardiovascular events; MDA: malondialdehyde; MVA:
mevalonate; NYHA: New York Heart Association; NT-proBNP: N-terminal pro–B-type natriuretic peptide; PMNs: peripheral blood
mononuclear cells; PKB: protein kinase B; SBP: systolic blood pressure; tChol: total cholesterol; TG: triglycerides; T2DM: type 2 diabetes
mellitus; VAS: visual analogue scale; 6MWT: 6-min walk test; HbA1c: glycated hemoglobin.
Table 2. The main properties of different natural compounds.
Plant BioactiveComponent Properties In Vitro/In Vivo Models Clinical Trials References
Brassicaceae family
Gramineae family Coenzyme Q10
Antioxidant and
anti-inflammatory activity
Key component of METC and in
ATP production
Bioenergetic effect





↓ Nox2 gene expression
↑ Vasodilation ↓ Aldosterone levels
↑ Fatty acid oxidation ↑ VLDL
↓ LDLc/HDLc ↓TC/HDLc
↓ Fibrinogen
↓ SBP ↓ DBP
- EPCs
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Table 2. Cont.
Plant BioactiveComponent Properties In Vitro/In Vivo Models Clinical Trials References
Citrus Bergamia
Risso et Poiteau BPF
↓ Serum glucose, TG, TC, LDL-C,
VLDL-C
↑ HDL-C ↑ fecal sterol excretion
Re-arrangement of
lipoprotein particles
↑ Lipid transfer protein system
↓ pCEH
↑ SOD, catalase
↓ SMC proliferation, LOX-1, p-PKB
↓ ROS, TBARS, MDA, Nitrotyrosine




↓ 8OHdG ↑ newly formed myocytes
- eCSCs













↓ CK-MB, GSSG, TBARS, LDH
↓MDA, 3-NT, ET-1, IL-1 β,
IL-6, TNFα
↑ eNOS ↓ PCs, iNOS
↑ p-Akt, p-AMPK ↑Prdx-1 and
Prdx-2 ↓ TC, TG
↑ SOD and GSH activity
↑ integrity of complex III of
the METC





↓ pMEK, pERK1/2, p53, p-IκBα
↑ pSTAT-3
↓ CYP2E1, OH-1, NF-κB, COX-2
↓ GRP78, CHOP
- VPCs
- CoCl2-induced hypoxia in
H9C2 cells
- ISO-induced MI in rats
- Myocardial I/R in rats
- Doxo-treated rats
- Myocardial I/R in
hypercholesterolemic rabbits
- Myocardial infarction in rats










↓ postprandial blood glucose
rise, HbA1c
↑ urinary glucose excretion
↓ urinary albumin excretion
↓ glycohemoglobin, insulin, TG
↑muscle GLUT4 ↓ renal GLUT2
↓ kidney epithelial vacuolization
↓ hepatic glucose production
↑ ketone bodies amount
- Isolated rabbit
coronary artery




- STZ-induced diabetic rats
[64–73]
Vitis vinifera Proanthocyanidins
free radical scavenging activity
↓ TBARS levels
↓ DNA fragmentation
↓ p53 ↑ Bcl-2, Bcl-XL
↓ liver toxicity and
DNA fragmentation
↓ hepatocyte apoptosis and necrosis
↓ JNK-1, c-Jun
↓cardiomyocyte apoptosis
↑ post-ischemic cardiac function
↑mitochondrial IDH, SDH,
MDH, α-KGDH




- Human oral keratinocytes
- AAP-induced liver injury
in mice
- Myocardial I/R in rats
[74–82]
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Table 2. Cont.







↑ SOD, GPx, CAT activity ↓MDA
↓ LDH, CK-MB, SGOT,
SGPT, Calcium
↑ cell viability
↑ Integrity of mitochondrial PTP
↑ Activity of mitochondrial
respiratory complexes
↑ oxygen consumption rate ↑ ATP
level ↓ HIF-1α
↑Mitochondrial OPA1, Mfn1, Mfn2
↓ Drp1 and Fis1
↓ Bax, Bad ↑ Bcl-2, p-Akt
↓ p-P38, p-JNK
↓ Heart rate ↓ cardiac fibrosis
↓ IL-6, TNFα, IL-1β, MCP-1 ↑ IL-10
↓ Nuclear traslocation of NF-κB
↑ coronary artery dilation ↑ ECG
- Myocardial ischemia in H9C2
- ISO-induced ischemia in rats - Angina pectoris [83]
Vitis vinifera Resveratrol
↑ oxygen consumption rate ↑ SIRT1
and p-AMPK
↓ PCG1α acetylation ↑ PCG1α
activity ↑ insulin sensitivity
↑ endothelial function ↑SBP ↑
adiponectin, IL-10
↓ PAI-1, hsCRP, TNF α, IL-6
↓ HbA1c, TC, TG ↓ number of
angina episodes
↑ LV diastolic function ↓ ANP
↑ LC3II/LC3I ↓p-mTOR, p-p70S6K
↑myocardial ATP content ↓
cleaved-caspase-3
- C2C12 mouse myoblast cells
















↑ increase, ↓ decrease. BPF, Bergamot Polyphenolic Fraction; METC, Mitochondrial Electron Transport Chain; ATP, Adenosine Tri-Phosphate;
AMPK, 5′ Adenosine Monophosphate-activated Protein Kinase; eNOS, endothelial Nitric Oxide Synthase; H0-1, Heme oxygenase 1; LV, Left
Ventricular; 3-NT, Nitrotyrosine; MDA, Malonildialdehyde; Nox2, NADPH oxidase-2; VLDL-C, Very Low Density Lipoprotein Cholesterol;
LDL-C, Low Density Lipoprotein Cholesterol; HDL-C, High Density Lipoprotein Cholesterol; TC, Total Cholesterol; SBP, Systolic Blood
Pressure; DBP, Diastolic Blood Pressure; TG, Triglycerides; pCEH, pancreatic Cholesterol Ester Hydrolase; SOD, Superoxide Dismutase;
SMC, Smooth Muscle Cells; LOX-1, Lectin-type Oxidized LDL receptor 1; PKB, Protein Kinase B; ROS, Reactive Oxigen Species; TBARS,
Thiobarbituric Acid Reactive Substances; 8OHdG, 8-Hydroxy-2′-deoxyGuanosine; GPx, Glutathione Peroxidase; CK-MB, Creatine kinase
isoenzyme; GSSG, Glutathione disulfide; LDH, Lactate Dehydrogenase; ET-1, Endothelin-1; IL-1β, Interleukin-1β; IL, Interleukin; TNF-α,
Tumor Necrosis Factor- α; PCr, Phospho-Creatine; iNOS, inducible Nitric Oxide Synthase; Prdx, Peroxiredoxin; GSH, Glutathione; GS3K-β,
Glycogen Synthase Kinase-β; Sirt-1, Sirtuin-1; FOXO3a, Forkhead box O3a; ERK1/2, Extracellular signal-Regulated Kinase 1/2; IκBα,
nuclear factor of kappa light polypeptide gene enhancer in B-cells Inhibitor-α; STAT-3, Signal Transducer and Activator of Transcription 3;
CYP2E1, Cytochrome P450 Family 2 Subfamily E Member 1; NF-κB, Nuclear Factor kappa-light-chain-enhancer of activated B cells; COX-2,
Cyclooxygenase-2; GRP78, Glucose-Regulated Protein 78; CHOP, C/EBP Homologous Protein; ox-LDL, oxidized-Low Density Lipoprotein;
HbA1c, glycated Haemoglobin; GLUT, Glucose Transporter; Bcl-2, B-cell lymphoma 2; Bcl-xL, B-cell lymphoma-extra large; JNK-1, c-Jun N-
terminal Kinase; IDH, Isocitrate Dehydrogenase; SDH, Succinate Dehydrogenase; MDH, Malate Dehydrogenase; α-KGDH, α-Ketoglutarate
Dehydrogenase; NADH, Nicotinamide Adenine Dinucleotide; CCO, Cytochrome C Oxidase; GPx, Glutathione Peroxidase, CAT, Catalase;
SGOT, Serum Glutamic Oxaloacetic Transaminase; SGPT, Serum Glutamic Pyruvic Transaminase; PTP, Permeability Transition Pore; HIF-1α,
Hypoxia-Inducible Factor 1-α; OPA1, Optic atrophy Protein-1; Mfn, Mitofusin 1; Drp1,Dynamin-related protein 1; Fis1, mitochondrial
Fission 1 protein; Bax, Bcl-2-like protein 4; Bad, Bcl-2 associated agonist of cell death; MCP-1, Monocyte Chemoattractant Protein-1; ECG,
electrocardiogram; PCG1α, Peroxisome proliferator-activated receptor gamma Coactivator 1 alpha; PAI-1, Plasminogen Activator Inhibitor;
Hs-CRP, High sensitivity C-Reactive Protein; ANP, Atrial Natriuretic Peptide; LC3, Microtubule-associated protein 1A/1B-light chain
3; mTOR, mechanistic Target Of Rapamycin; EPCs, Endothelial Progenitor Cells; HF, Heart Failure; eCSCs, endogenous Cardiac Stem
Cells; Doxo, Doxorubicin; VPCs, Vascular Progenitor Cells, ISO, Isoproterenol; MI, Myocardial Infarction; I/R, Ischemia/Reperfusion;
T2DM, Type 2 Diabete Mellitus; STD, Streptozotocin; TPA, 12-O-tetradecanoylphorbol-13-acetate; RNS, Reactive Nitrogen Species; AAP,
acetaminophen; HFD, High Fed Diet; HFrEF, Heart Failure with reduced Ejection Fraction; MetS, Metabolic Syndrome; CHD, Chronic
Heart Disease; CAD, Coronary Artery Disease.
Therefore, although the use of nutraceutical supplementation is of interest in the
prevention and treatment of cardiovascular disease, the potential for its use in the treatment
of HF still needs to be adequately assessed. More studies are required to verify the
optimal use of nutraceutical supplementation in counteracting myocardial dysfunction in
HF patients.
The aim of this review article is to assess the pathophysiological mechanisms involved
in the early stages of HF and the potential for timely nutraceutical supplementation
to support the failing myocardial cells in tandem with the pharmacological and non-
pharmacological interventions currently being used. Moreover, a further objective is to
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optimise nutraceutical intervention through the identification of candidate natural extracts
to be used in future clinical studies in patients experiencing HF.
2. Emerging Pathophysiological Mechanisms Involved in the Onset of HF
2.1. Energy Deficiency and Mitochondrial Impairment in HF
In patients with HF, energetic deficits are palpable and can be detected, both in vivo
and in vitro, in the early stages of the disease [94]. In particular, it has been reported that
non-invasive measurement of the myocardial phosphocreatine (PCr) via 31P-magnetic
resonance spectroscopy (MRS) and an assessment of the PCr to adenosine triphosphate
(ATP) ratio indicate an energy shortage, which is associated with many cardiac disease
states, including ischemic heart disease and cardiomyopathies [95]. In this context, the
degradation of ATP, which is frequently associated with diastolic dysfunction, represents
a biomolecular target of HF with a preserved ejection fraction (HFpEF) and indicates the
occurrence of an increased energetic demand and/or energetic mismatch in HF [96–101].
This occurs at the early stages of the disease, thereby showing that counteracting the
energy deficit may be crucial in the development of HF, though the mechanisms of energy
impairment need to be better assessed.
Several studies, ranging from those conducted 50 years ago at the National Institute of
Health (NIH) to more recent studies [102–105], have suggested that the electron transport
chain (ETC) function is not impaired in failing versus not-failing hearts, although conflict-
ing data exist [106]. Studies on the role of Krebs cycle activity, which is responsible for the
production of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide
(FADH2) from acetyl-coenzyme A, have shown an impairment of this energy-producing
pathway in decaying hearts [104,107]. This effect is accompanied by an impaired spatial
pattern, which characterises mitochondria within cardiac cells. In particular, energy de-
pletion affects mitochondrial functionality. This is shown by the expression of a class of
fusion proteins, such as mitofusins (Mfn1 and Mfn2), which also potentially affect the
Sarcoplasmic Reticulum (SR)-mitochondrial Ca2+ microdomain [108–110], and this, in turn,
is accompanied by dysregulation of the mitochondrial Ca2+ uniporter (MCU), seen by
means of a mouse model of pressure overload [111].
Together, these data indicate that in HF, Ca2+-induced stimulation of the Krebs cycle
is impaired by decreased mitochondrial Ca2+ uptake during cardiac workload transitions.
Mitochondrial functionality is also crucial in the balance between energy production
and the consistent anti-oxidative capacity of failing cardiomyocytes [112,113]. In particular,
it is well-known that the oxidation of NADH, which occurs during an elevated cardiac
workload, is an important consequence of this energy supply and demand mismatch [114].
The depleted NADPH-coupled anti-oxidative capacity is then overwhelmed by reactive
oxygen species (ROS) production by NADH-coupled respiration in the electron transport
chain (ETC) [115,116]. Consequently, this favours the reverse mode of the mitochondrial
nicotinamide nucleotide transhydrogenase (Nnt), thus dissipating the anti-oxidative capac-
ity [115]. Aon et al. proposed that “mitochondria have been evolutionarily optimized to
maximize energy output while keeping ROS overflow to a minimum by operating in an
intermediate redox state” [116].
Therefore, extreme oxidation, as aforementioned, and a reduction in the mitochondrial
redox state, such as that which occurs during ischaemia, are to be avoided in order to
achieve optimal conditions for cardiac mitochondria. However, the working heart con-
stantly produces adenosine diphosphate (ADP), physiologically accelerating respiration
and increasing oxidation in the respiratory chain. Therefore, it is unlikely that increased
oxidative stress in HF is solely due to a net increase in ROS production, but rather due
to a diminished ROS-scavenging capacity [117]. This leads to a vicious circle, increasing
oxidative stress by exacerbating the mismatch in the energy supply and demand [118].
Mitochondria contain unsaturated fatty acids, iron sulphur clusters, densely packed pro-
teins, and multiple copies of mitochondrial DNA (mtDNA), all of which are essential to the
mitochondrial function and typical targets of oxidative damage [119]. The most vulnerable
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to oxidative damage, due to their proximity to ROS production, are the ETC complexes,
which include cardiolipin [120]. Moreover, oxidative stress triggers the peroxidation of
cardiolipin, thereby impairing cristae formation [121]. On the other hand, the respirasome
and the detachment of cytochrome c, which is a mobile electron carrier in the inner mi-
tochondrial membrane (IMM), are also affected by the peroxidation of cardiolipin [122].
Mitochondrial DNA is associated with the IMM and vulnerable to oxidative damage due
to the lack of protective histones. Furthermore, damage to mtDNA results in ATP synthesis
reduction, reduced ETC activity and a further increase in electron slippage to oxygen,
thus setting up a feed-forward cycle of ROS-induced ROS production [123–125]. Hence,
at the centre of an efficient cardio-protection strategy, in the early stages of HF, is the
preservation of the functionality of the mitochondria in cardiomyocytes, which represents
a consistent challenge.
2.2. Endoplasmic Reticulum Stress in HF
As previously shown for the role of mitochondrial dysfunction, stressful conditions
occurring at the level of the endoplasmic reticulum (ER) stress also seem to play a crucial
role during the early phases of HF [126–128]. In particular, there is evidence that ER
impairment is accompanied by enhanced oxidative stress which, in turn, is connected to
various cardiovascular conditions, such as cardiac hypertrophy and, at the late stages,
HF [129,130].
ER and mitochondria are capable of regulating oxidative stress. In particular, in models
of heavy-metal-induced myocardial dysfunction, an increase in the level of stress markers of
ER occurs. This implies that oxidative stress and heart dysfunction are connected to extreme
ER stress. Moreover, data have shown that when induced by excessive ER stress, protein
damage and intracellular calcium ion (Ca2+) anomalies trigger heart dysfunction [130,131].
Several toxicants potentially contribute to heart injury via this mechanism. The effect of
these toxicants can be counteracted by natural antioxidants which efficiently revive ER
stress levels in the heart. Hence, by regulating the ER-related pathway, natural antioxidants
can exert a protective role against cardiotoxic agents via a significant reduction in ER
stress. The mechanism of cardioprotection obtained by means of natural antioxidant
supplementation can possibly be explained by regulation of the ER-related pathway. In
particular, it has been found that ER and oxidative stress lead to impairment of the so-called
unfolded protein response (UPR), which is a compensatory mechanism that contributes to
maintenance of the myocardial cell integrity. This involves complex molecular pathways,
probably driven by eukaryotic translation initiation factor 2 alpha (eIF2α) phosphorylation
and protein kinase RNA-like ER Kinase (PERK) and leading to a compensatory response to
ER stress, although this needs to be better clarified [130–136]. Furthermore, an increase in
intracellular Glucose-Regulated Protein 78 (GRP78), considered to be a chaperone of ER
stress and, most importantly, a regulator of UPR, has been shown to play a role in these
mechanisms [132–136].
Therefore, it is likely that active ingredients of plant extracts, once given at an appro-
priate dosage and formulated to obtain the due concentration at the active site of action,
may produce a beneficial effect to counteract cardiomyocyte ER stress.
2.3. Imbalanced Metalloproteinase Regulation in HF
The extracellular cardiac matrix (ECM), which is a complex architectural network,
maintains a balance between the degradation and deposition of matrix proteins by pre-
serving the correct cardiac geometry whilst also allowing the myocardium to maintain its
structural integrity [137]. The ECM aids in the proper functioning of heart cells, forming
a specific scaffold which allows for the anchoring of these proteins [138]. A range of
physiological and pathological processes, such as cell proliferation and differentiation,
and tissue morphogenesis, are influenced by the ECM turnover [139]. The ECM is also
responsible for the transduction of mechanical forces within the cardiac vessels and heart,
and for promoting diastolic compliance in the arterial wall.
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Matrix metalloproteinases (MMPs) are enzymes capable of degrading both of the
ECM structural proteins being modulated by metalloproteinase endogenous tissue in-
hibitors (TIMPs). These are the fundamental mediators of ECM remodelling. In normal
circumstances, these processes are highly regulated. The roles of MMPs and TIMPs can
be both positive and negative in cardiac remodelling [138,139], with TIMPs controlling
MMPs, minimising the degradation of the matrix. The MMPs play a pathological and
irreversible role in remodelling ECM, which is important in both compensatory cardiac
hypertrophy and acute decompensated heart failure [140]. MMPs also mediate the ven-
tricular remodelling caused by myocardial infarction or viral myocarditis [140]. Several
studies indicate that the serum level of metalloproteinase-2 (MMP-2) is an autonomous
predictor of mortality in HF patients [141]. MMPs are made up of five main groups, in-
cluding gelatinases, collagenases, matrilysins, stromelysins, and metalloproteinases of
membrane-type/membrane-type MMPs. The divisions of these groups are based upon
their structure and the specificity of the substrate [142]. Two of these—Gelatinase A and
Gelatinase B, (also known as MMP-2 and MMP-9, respectively)—are directly involved in
the pathogenesis of coronary thrombosis, atherosclerosis, myocardial infarction, and heart
failure [143]. Furthermore, MMP-2 causes migration of the cell, growth, differentiation, and
inflammation [144]. These enzymes cleave structural proteins from the elastin and collagen
networks. The known spectrum of substrates for MMP-2 not only contains the components
of extracellular matrixes, such as collagens or elastin, but MMP-2 is also able to digest parts
of the contractile apparatus, such as the myosin 1 light chain or troponin I [143]. It has been
proven that, during ischaemia, the proteolytic function of MMPs in myocardium generally
increases. Moreover, alterations in the balance of MMPs and TIMPs could contribute to
acute myocardial ischaemia-reperfusion injury [145]. Conversely, MMP-2 is associated with
myocardial dysfunction, contributing to the development of cardiomyopathies [146–150].
The occurrence of an imbalanced regulation of the NT-truncated intracellular isoform of
MMP-2 (NT-MMP-2) as a consequence of mitochondrial dysfunction and oxidative stress
seems to be involved in myocardial injury [151,152]. Due to the strong connection between
NT-MMP and the mitochondria, it is likely that pathophysiological events, subsequent
to hyperglycaemia, may underlie a cascade of events mediated by oxidative stress which
are associated with mitochondrial dysfunction [152–154]. These events cause an altered
modulation of MMPs and, at the end stage, lead to failing myocardium, such as that which
can be seen in the hearts of diabetic patients.
Recently, we examined an exaggerated production of superoxide anion (NADPH
oxidase-dependent), which occurs in hyperglycaemic rats, gradually impairing the function
and myocardial structure [155]. In particular, we found that during the initial stage of
cardiac injury brought on by chronic hyperglycaemia, the reduced fractional shortening and
ejection fractioning are associated with biochemical changes, suggesting the involvement
of mitochondrial functionality. In particular, in a model of streptozotocin (STZ)-induced
hyperglycaemia, we found that increased ROS production is accompanied by an increased
expression of the mitochondrial translocator protein (TSPO): a protein located at the level
of the outer mitochondrial membrane [154–156] which has been found to be imbalanced in
post-ischemic cardiac damage [157]. Moreover, STZ-induced hyperglycaemia is associated
with an increased expression of selective Voltage-Dependent Anion Channel-1 (VDAC1),
which contributes, alongside TSPO, to the regulation of calcium traffic at the level of the
transition pore of the mitochondrial membrane. Under these experimental conditions,
MMP-2 was downregulated and NT-MMP2 was found to translocate at the level of the
mitochondrial membrane, thereby suggesting that these mechanisms could contribute
to functional changes seen in the heart of hyperglycaemic rats. These effects may be
counteracted by natural antioxidants (see below).
2.4. The cGMO/NO Pathway in HF
There is evidence that, through important roles in the cardiac myocyte, nitric oxide
(NO), nitric oxide synthase (NOS), and soluble guanylate cyclase (sGC) all oppose patho-
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logical remodelling when functioning normally [158]. A large body of work supports
that in HF and in conditions predisposing to HF, NO, which is the activator of soluble
guanylate cyclase, also becomes dysregulated [159]. The cardiovascular tissue release
of NO can be directly reduced by ROS in the absence of effects on NOS expression and
activity [159]. Correspondingly, human studies have shown that there is a predisposition
to HF in conditions associated with reduced endothelial NO release. These reduced en-
dothelial NO release conditions include ageing, diabetes, and obesity [160]. In fact, based
on these human data, a current proposed model postulates that the pathogenesis of HFpEF
is driven by the generation of reduced NO-induced cyclic guanosine monophosphate
(cGMP) [161,162]. Animal models have also shown that endothelial nitric oxide synthase
(eNOS) becomes uncoupled not only in hypertension [163], but also in a pressure overload
stress model [164]. This promotes the production of pathologic reactive oxygen species
(ROS), rather than NO. Additionally, under conditions of oxidative stress and multiple
HF risk factors, soluble guanylate cyclase can be directly modified and rendered unable
to generate cGMP in response to NO. In fact, in a pressure-overload stress model, it has
been reported that the translocation of sGC is involved in sGC oxidation and contributes to
depressed NO-stimulated sGC activity [164].
Moreover, the failing heart not only exhibits changes in cGMP catalysis through the
upregulation of cGMP-specific phosphodiesterases (PDEs), but also alterations in sGC
augmentation. Part of an 11-member family, PDEs (PDE1 to PDE11) catabolise cAMP,
cGMP or both, depending on the specific PDE [165]. Recently, PDE5 and PDE9, both of
which are cGMP-specific PDEs, have been studied. According to samples taken from end-
stage failing myocardium, PDE5 expression increased in the failing human left ventricular
(LV) [166]. Furthermore, in the LV of mice subjected to experimental transverse aortic
constriction (TAC), aside from protein expression, the total cGMP phosphodiesterase
activity increased [167]. Studies on pharmacological and genetic manipulation in mice
have also confirmed the pro-remodelling role of the enzyme in the cardiomyopathies
and the effectiveness of PDE5 inhibition in opposing cardiac remodelling [165]. More
recently, in the failing human LV, an increase in the cGMP-selective PDE9 was observed
in both Reduced as well as Preserved Ejection Fraction Heart Failure (HFrEF and HFpEF,
respectively). This was observed in the LV of mice subjected to TAC as well. After thoracic
or abdominal aortic constriction, as well as in response to isoproterenol infusion, genetic
deletion or pharmacological inhibition of PDE9, LV remodelling improved [168,169].
The aforementioned observations describe a general model in which alterations in
components of both cGMP-generating and anti-cGMP-generating components lead to a
net reduction in myocardial cGMP, subsequent cardiac remodelling and failure. Studies
on the myocardial tissue of HFpEF patients, compared with that of not-failing tissue
patients with aortic stenosis or with HFrEF tissue, have demonstrated a reduced cGMP
concentration [170]. Reduced myocardial cGMP has also been observed in a rat model
of HFpEF [171], and tissue from patients display increased PDE9A and cGMP-esterase
activity [170]. On the other hand, in the presence of PDE5 and PDE9 inhibition, numerous
animal studies have also identified a net increase in cGMP [168,169]. Therefore, the rationale
behind pharmacological and nutraceutical strategies to augment intracellular cGMP in
patients with HF is supported by animal studies of cGMP regulating molecules and direct
observations in humans with HF.
2.5. HF and Sodium-Glucose Cotransporters
Evidence has been provided demonstrating that sodium–glucose cotransporter (SGLT2)
inhibitors may produce benefits in cardio-renal dysfunction in diabetic patients. This
has been assessed by means of an extensive review by Verma and McMurray reporting
large-scale clinical trials of type 2 diabetes mellitus (T2DM) patients with either multiple
cardiovascular risk factors or established cardiovascular disease [172].
In particular, it has been reported that many of the potential benefits of regulating
SGLT2 in both diabetic and non-diabetic patients with HF have been attributed to the
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slowing of the atherothrombotic processes which accompany type 2 diabetes mellitus
(T2DM), and the improvement in the cardio-renal consequences of T2DM, which can
lead to myocardium decay. Moreover, recent evidence suggests that SGLT2 modulation
is accompanied by additional effects which may be beneficial to HF management. In
particular, it has been postulated that SGLT2 inhibitors may improve and/or optimise
cardiac energy metabolism.
These agents may provide improvement in the cardiac output and cardiac efficiency
by acting on the substrate efficiency and myocardial energetics [172]. Furthermore, in the
presence of T2DM and/or HF, it has been suggested that the metabolic flexibility of the
heart is impaired as it relates to substrate utilisation [173].
A build-up of free fatty intermediates may result from an over-reliance on non-
esterified fatty acids (NEFAs) as a substrate for ATP generation. This action may also
promote the development of diastolic dysfunction and lipotoxicity [174].
In those with diabetes, SGLT2 inhibitors may offer an optimal alternative myocardial
fuel source [175]. This alternative fuel source is more cost-effective in those with T2DM, as
SGLT2 inhibitors are known to promote ketone body β-hydroxybutyrate (βOHB) produc-
tion [176]. It has been postulated that elevated ketone levels may be the result of an effort
to increase glucagon levels through a possible decrease in βOHB excretion via the kidneys.
The concept underlying this is that ketone-body βOHB is a “super fuel”, oxidised by the
heart instead of glucose and NEFAs. In the failing heart, ketones may improve the cardiac
function and increase the mechanical efficiency [177,178]. This is an interesting postulate,
although cogent data supporting this thesis are scarce. Preliminary studies carried out in
pigs following myocardial infarction showed that empagliflozin increases the consumption
of myocardial ketone while simultaneously reducing the production of lactate, as well as
the consumption of cardiac glucose [179]. Another hypothesis is that this is due to the inhi-
bition of histone deacetylase, promoting increases in the levels of SGLT2-inhibitor-induced
βOHB and preventing pro-hypertrophic transcription pathways [180].
It is also possible that a decrease in βOHB oxidation promotes a decrease in acetyl-CoA,
which is a derivative of ketone oxidation. These decreased levels, in turn, increase glucose-
derived pyruvate oxidation and thus improve myocardial glucose metabolism. A decrease
in the supply of acetyl-CoA may result in an improved production of mitochondrial
energy and, consequently, in a decrease in the harmful hyperacetylation, thus aiding the
mitochondrial enzymes [180].
It has been postulated, using an untargeted metabolomic approach, that the inhibition
of SGLT2 promotes the degradation of branched-chain amino acid (BCAA), which may
provide an alternative source of fuel to the failing myocardium. In HF patients, the impaired
degradation of BCAA in myocardium may contribute to aberrant bioenergetics [181]. As
intriguing as these findings are, it must be noted that we currently lack definitive evidence
that links the beneficial effects of SGLT2 inhibition to myocardial energetics.
A promising emergent hypothesis is that direct inhibition of the Na+/H+ exchanger
(NHE) 1 isoform in the myocardium may be an effect of SGLT2 inhibition and consequential
effects on Na+/H+ exchange in the myocardium [182,183].
In experimental models of HF, it has been demonstrated that NHE1 activation results
in increased cytosolic sodium and calcium. Recently, Ulthman et al. demonstrated that the
cardiomyocyte NHE is inhibited by the SGLT2 inhibitor empagliflozin, thereby increas-
ing mitochondrial calcium levels while reducing the levels of cytoplasmic sodium and
calcium [183].
In the heart, the mechanism by which these effects occur on cardiomyocyte NHE
remains elusive, as SGLT2 receptors are not expressed. Notably, it has been suggested that
natriuresisis is promoted in the proximal tubule by SGLT2 inhibitors, which downregulate
the NHE3 activity [184]. In HF patients, the expression of NHE3 is increased and known to
mediate the reuptake of tubular sodium. As an additional mechanism, the inhibitory effects
on NHE3 may serve to reduce cardiac failure and restore whole-body sodium homeostasis.
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Hence, prevention and/or treatment of HF may be possible by these agents through a
common cardio-renal mechanism, such as the inhibition of NHE1 and NHE3 [182].
Cardiac fibrosis and SGLT2 inhibition are widely regarded as common final pathways
through which HF develops. Cardiac structural remodelling is universally involved in this
mechanism due to the deposition of ECM proteins by cardiac fibroblasts, which accelerate
the development of HF by impeding ventricular compliance [185]. Recent experimen-
tal data on myocardial infarction showed the significant cardiac anti-fibrotic effects of
dapagliflozin on the suppression of collagen synthesis, an effect made possible by the in-
creased activation of M2 macrophages and inhibition of myofibroblast differentiation [186].
Additionally, preliminary studies, using human cardiac fibroblasts measured by the colla-
gen fibre alignment index, have demonstrated that empagliflozin significantly attenuates
the activation of TGF-β1-induced fibroblasts while reducing cell-mediated ECM remod-
elling [187]. Moreover, evidence demonstrates that empagliflozin suppresses the expression
of multiple key pro-fibrotic markers, including type I collagen, α-smooth muscle actin, the
connective tissue growth factor, and MMP-2 [187]. Therefore, an emerging postulate is
that the inhibition of SGLT2 may have direct and favourable effects on one of the most
important factors of HF—the cardiac fibroblast phenotype and function. These effects
indicate potential for using nutraceutical supplementation with natural SGLT2 inhibitors,
such as a phlorizin-rich apple extract.
2.6. Impairment and Senescence of Cardiac Stem Cells in HF
It is known that myocardial infarction and ischaemic heart disease are the major deter-
minants for the development of HF [188,189]. Furthermore, where HF is of a nonischaemic
origin, in cases of structural and “functional” cardiomyopathies, the lack of myocardium
is the primary issue to be addressed for a robust cardiomyocyte replacement [190,191].
Regenerative medicine aims to find a therapy that is both effective and broadly available
to refresh the contractile muscle cells lost and/or rendered permanently dysfunctional
as a consequence of the primary injury [190,191]. Unfortunately, the predominant scepti-
cism about the intrinsic endogenous regenerative capacity of the adult mammalian heart,
including the human heart, has produced often contradictory approaches in myocardial
repair/regeneration [191]. This skepticism can only be overcome if hard, clean and clear
scientific data are obtained, thereby eliminating the need for interpretations and opinions.
It is unlikely that any clinical repair or regeneration protocol will ever be able to answer the
question regarding the feasibility of functionally regenerating the failing human heart [191].
It is well-known that the mammalian heart, including the human heart, contains a pool
of resident tissue-specific cardiac stem/progenitor cells—the endogenous Cardiac Stem
Cells (CSCs)—referred to as eCSCs when in the myocardium, and CSCs when isolated
and studied in vitro [192–194]. The eCSCs have been identified as a small cardiac cell
population through the expression of specific membrane markers, in particular, the stem
cell factor (SCF) receptor kinase c-Kit [195], Sca-1 [196], and MDR-1 [197]. In vitro and
in vivo experiments have clearly shown that CSCs, being multipotent, clonogenic, and
self-renewing, have all the characteristics expected of a tissue-specific stem cell. Differen-
tiation of the main myocardial cell is possible in vivo and in vitro [192]. Several studies
have reproduced the findings that while the exhibition of c-Kit cell dysfunction is present
in W locus mouse mutants (W/Wv) [198], c-Kit signalling in vitro promotes the survival,
growth, and proliferation of human CPCs [199]. Indeed, W/Wv mice display impaired car-
diac recovery after infarction [200], diminished cardiac function with advanced age [201],
and compromised c-Kit cell differentiation into cardiomyocytes [202]. Blunted reparative
responses were exhibited in both myocardial injuries in bone marrow c-Kitpos cells from W
locus mutants and in vitro cells with silenced c-kit [198].
Furthermore, deletion of the c-Kit gene, as it occurs in homozygous W-mutated
mice [200], causes premature murine death, because c-Kit gene deletion is incompatible
with life. However, during embryonic life, c-Kit-defective adult mouse hearts appear to
develop normally [203], while adult myocardial infarction model c-Kit Cre-KI mice have
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demonstrated a significant defect in the regeneration potential [204]. Therefore, it appears
that the roles that c-Kit plays in cardiac regeneration are different to those it plays in heart
formation/development. This suggests that the molecular mechanism underlying cardiac
regeneration differs from that of cardiac generation. Despite all of the attempts that are
currently ongoing to decode the pathways of developmental cardiac generation and neona-
tal heart regeneration to instruct effective protocols of adult cardiac regeneration, cardiac
generation has still not been predicted [205]. Finally, the role of c-Kit in cardiac pathology
was evaluated in several models, such as aging cardiomyopathy [206,207], doxorubicin-
induced cardiomyopathy [208], and chronic heart failure [209,210]. In particular, Huang
et al. developed a “paediatric” model of doxorubicin-induced cardiotoxicity, in which
juvenile mice were exposed to doxorubicin (DOXO) using a cumulative dose that did not
induce acute cardiotoxicity [211]. These juvenile mice developed normally and had no
obvious cardiac abnormalities as adults. However, these hearts did have reduced numbers
of c-Kitpos cardiac cells and abnormal vasculature, which correlated with an increased
sensitivity to stimuli, both physiological and pathological. When subjected to myocar-
dial infarction, adult mice developed a more pronounced cardiac decompensation, which
correlated with a failure to increase the capillary density in the injured area. It was subse-
quently demonstrated that DOXO-induced cardiomyopathy is due to a depletion of the
functional c-Kitpos CSC pool, and can be rescued by restoring its function via nutraceutical
supplementation [212].
3. Candidates for Nutraceutical Supplementation in the Failing Myocardium
according to the Aforementioned Emerging Mechanisms
3.1. Coenzyme Q10
Coenzyme Q10 (CoQ10), also defined as ubiquinone (in the oxidised form) or ubiquinol
(in the reduced form), plays a key role in the functioning of the MC. CoQ10 is responsible
for the transfer of electrons from complex I and II to complex III, thus promoting ATP gener-
ation [213] (Figure 1). Moreover, CoQ10 is involved in the so-called proton motive Q-cycle,
which enables the passage of protons across the internal mitochondrial membrane [214].
Q10 has a highly lipophilic molecular structure and is related to vitamin K, where “Q”
represents quinone and “10” refers to the 10-isoprene group. [215]. CoQ10 is ubiquitous in
most mammalian tissues, with particularly high levels in organs, such as the heart, with
the highest rate of metabolism [215]. The higher concentration of CoQ10, compared to
other carriers, balances its slower cyclic oxidation/reduction rate [30]. Therefore, CoQ10
deficiency in the cardiac mitochondria leads to the dysfunction of mitochondrial respira-
tion. Conversely, CoQ10 supplementation could improve the mitochondrial function [18].
Preclinical data suggest that CoQ10 has important anti-inflammatory properties and is
able to protect endothelial function from damage [19]. In fact, CoQ10 also regulates eNOS
function in different cellular membranes. Therefore, the depletion of CoQ10 can promote
the uncoupling of eNOS, making it an additional source of ROS and thereby shifting the
nitrous–redox balance towards oxidation [20].
Interestingly, data have demonstrated a protective role of CoQ10 in high glucose-
induced endothelial progenitor cell (EPC) dysfunction [31]. In particular, the administration
of CoQ10 reduces apoptosis cell death and increases the mitochondrial membrane potential.
In addition, CoQ10 is able to reduce ROS production, enhancing eNOS/Akt activity and
upregulating HO-1 expression [31] (Figure 2).
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protein kinase (AMPK) pathway, upregulating endothelial nitric oxide synthase (eNOS) activity and heme oxygenase-1
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Physiologically, about 50% of CoQ10 is ingested, while the remaining 50% is en-
dogenously synthesised through the mevalonate pathway, which is inhibited by a statin
action [32]. Indeed, in isoproterenol-induced HF in rats, Garjani et al. showed a severe LV
dysfunction when the animals were treated with a high dose of atorvastatin. Conversely,
it has also been reported that the co-administration of CoQ10 with a lower dose of ator-
vastatin ameliorates myocardial necrosis and fibrosis and the hemodynamic depression,
improving left ventricular (LV) dysfunction [33]. Hence, patients with a cardiovascular risk
and/or disease treated with statins may experience CoQ10 deficiency [18]. In patients with
HF, the severity of disease is correlated with CoQ10 deficiency [34]. Experimental evidence
suggests that lipid peroxidation, resulting from oxidative stress, causes a reduction in
CoQ10 levels [35]. At first, in a preliminary clinical study conducted in patients with HF,
CoQ10 was defined as an independent predictor of mortality [36]. However, this was not
confirmed by the data obtained from the larger CORONA study.
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According to the results of the CORONA study, the treatment of patients with rosu-
vastatin failed to reduce nonfatal myocardial infarction, nonfatal stroke due to ischaemic
cardiomyopathy, and the primary endpoint of death from cardiovascular causes [37].
However, the treatment of patients with rosuvastatin did reduce CoQ10 concentrations.
Nevertheless, the administration of rosuvastatin in patients with a low baseline of CoQ10
did not lead to a worse outcome [37]. In accordance with this, CoQ10 deficiency was not
considered an independent prognostic factor in HF [37]. In light of this evidence, CoQ10
deficit could play a causal role in patients suffering from HF, even those not treated with
statins. CoQ10, as an established mitochondrial therapy, ameliorates CoQ10 biosynthesis
defects through the constant dosing of CoQ10 dietary supplementation [38]. However,
despite the lack of firm evidence of its benefit in cardiovascular diseases, CoQ10 supple-
mentation has been studied for several decades. Though several clinical trials have shown
that CoQ10 may enhance Left Ventricular Ejection Fraction (LVEF), other well-designed
studies are needed to assess its effect on patient outcome [21]. Recently, in the Q-SYMBIO
trial, the effects of CoQ10 were studied in 420 patients with systolic HF. The results showed
a significant amelioration in symptoms and a substantial decrease in major adverse car-
diovascular events [21]. However, the study was underpowered and failed to provide
enough evidence of a benefit in this population. Therefore, it is still unclear whether CoQ10
administration benefits the outcome and symptoms in HF [21,22]. Moreover, in the recent
guidelines on the treatment of HF, there is no mention of CoQ10 [19].
3.2. Bergamot Polyphenols
Evidence has been collected showing that bergamot fruit (both juice and albedo)
produce beneficial effects in the cardiovascular system [24,39–44]. In fact, being rich in
polyphenols, bergamot derivatives produce an antioxidant response both in vitro and
in vivo, leading to a reduction in cholesterol, glucose and triglyceride serum levels, which
is an effect accompanied by a reduction in systemic inflammation and, subsequently, an
improvement in the endothelial function. These effects were confirmed in patients, mostly
by means of a bergamot polyphenolic fraction (BPF) extract, which displayed a potent effect
in modulating the liver traffic of lipoproteins and was able to counteract Non-Alcoholic
Liver Disease (NAFLD). The major components of BPF are naringin, neoeriocitrin and
neohesperidin and glycosylated polyphenols, such as bruteridin and melitidin, which
have been found to produce the inhibition of 3-hydroxy-3-methyl-glutaryl Coenzyme A
(HMGCoA) reductase [23,25,45,46].
Recent data published by Carresi et al. have also shown that BPF treatment leads to
relevant benefits in doxorubicin (DOXO)-induced cardiac damage in rats, preserving LV
contractility and attenuating pathologic myocardial remodelling [212]. Intriguingly, our
data show that BPF strongly prevented the induction of ROS, the excessive expression of
pro-autophagic mediators, and myocyte apoptotic cell death. Moreover, there is evidence
that BPF is able to attenuate attrition in cardiac-resident stem cells (eCSCs), promoting
newly formed myocytes in DOXO-treated rats [212].
In fact, Carresi et al. showed, for the first time, that BPF is also able to attenuate
attrition in endogenous cardiac stem cells (eCSCs), thereby improving the number of
resident c- KitposCD45negCD31neg eCSCs. On the other hand, BPF inhibited 8-hydroxy-
2′-deoxyguanosine (8-OHdG) nuclear accumulation, and promoted the replenishment
of cardiomyocytes with an increased number of small, newly formed BrdUpos myocytes
after DOXO administration [212] (Figure 2). This fits with previous experimental evidence
correlating DOXO-induced cardiac damage with stem cell impairment. Indeed, Burridge
et al. showed, in patients with breast cancer undergoing DOXO-induced cardiotoxic-
ity, that human-induced pluripotent stem-cell-derived cardiomyocytes are compromised
by atrcaciclyne treatment [216]. In addition, it has recently been reported that the in-
travenous administration of cardiac progenitor cell-derived exosomes protects against
doxorubicin/trastuzumab-induced cardiac toxicity [217].
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Therefore, the main findings from the Carresi et al. study revealed the highly beneficial
cardio-protective effects of BPF against DOXO-induced cardiomyopathy through its direct
scavenging and antioxidant properties.
The antioxidant effect of BPF enables it to interfere with the production of DOXO-
induced free radicals, excessive autophagy activation, and apoptosis, thus preventing
the compensatory mechanisms and pathological changes that lead to the development of
cardiomyopathy.
Overall, these data show a widely beneficial effect, highlighted by BPF, not only on
cardiomyocytes, but also likely on the population of endogenous cardiac stem cells (eCSCs).
These findings likely represent only part of the cardio-protective effects of bergamot-
derived polyphenols.
BPF has clear protective effects on the heart and is likely involved in the maintenance
of functional endogenous cardiac stem cells. Even if some of the protective effects of BPF
can be clearly attributed to its direct scavenging and antioxidant properties, the protective
molecular mechanism involved in the maintenance of resident endogenous cardiac stem
cells is not yet fully understood.
Further work is required to understand the specific molecular and genetic mechanisms
underlying the onset of cardiomyopathy induced by DOXO and to confirm our findings
on the role of BPF in cardio-protection.
3.3. Olea Europea L. Extract
Several studies credit the Olea Europaea leaf extract (OLEX) for the majority of the
beneficial effects that the Mediterranean diet has on human health [218–222]. Initially, the
richness of monounsaturated fatty acids (MUFA), and in particular that of oleic acid, was
considered the major healthful characteristic of OLEX. Following other observations made
for various aliments rich in MUFA, such as sunflowers, rapeseeds, and soybean, it is quite
clear that none of those aliments are comparable to OLEX as healthy food [223,224], even
when taking the role of some “minor components” into consideration. The compounds
found in OLEX, when consumed in crude form, are able to maintain their biological
activity. In the unsaponifiable fraction of olive oil, there are more than 200 “minor com-
ponents”. These minor components represent about 2% of the total weight and include a
number of heterogeneous compounds that are chemically unrelated to fatty acids [225,226].
Recently, the nutraceutical properties of OLEX compounds and the antioxidant activity
provided by these compounds have been the focus of a great amount of attention. In
OLEX, the most abundant antioxidants are lipophilic and hydrophilic phenols [227], which
are normally synthesised by the plant to react to various insect injuries and/or pathogen
attacks [228,229].
Nutraceutical properties have mainly been attributed to secoiridoid oleuropein (OL)
and its derivatives; the main alcohol 3, 4-dihydroxyphenyl ethanol, also known as hydrox-
ytyrosol (HT); and p-hydroxyphenyl ethanol or tyrosol [48,230]. These compounds are
released during the extraction process from the olive drupes into OLEX. In particular, OL
is abundant in unprocessed olive leaves and drupes, while a higher concentration of HT
may be found in the drupes and in olive oil, due to chemical and enzymatic reactions that
occur in the plant during maturation of the fruit [49,50]. In addition, many agronomic
factors may influence the final concentration in OLEX, such as the geographic origin of
olive drupes, cultivar, olive tree irrigation, and ripening stage, as well as the various oil
extraction conditions during crushing, malaxation, and OLEX separation [50].
The in vivo antioxidant activity of OL and HT is related to their high levels of bioavail-
ability [51,52]. Various studies have documented a high degree of absorption of both
compounds, which is fundamental to exerting their metabolic and pharmacokinetic prop-
erties [48]. OL and HT behave as antioxidants acting as anti-oxygen radicals, free radical
scavengers, radical chain-breakers, and metal chelators. They can break peroxidative
chain reactions and scavenge the peroxyl radicals with their catecholic structure, pro-
ducing stable structures [53]. In vitro studies have shown a decrease in ROS production
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after treatment with OL or HT, suggesting a chelating action on such metal derived from
copper-ion-induced oxidised low-density lipoprotein (oxLDL) [54]. Furthermore, in rats
treated with doxorubicin (DOXO), it has been observed that OL could prevent cardiomy-
opathy [55]. In addition, Granados et al. have reported that in rats with breast cancer,
HT attenuated DOXO-associated chronic cardiac toxicity, thus ameliorating mitochondrial
dysfunction [56]. In particular, HT treatment significantly prevents mitochondrial swelling
and vacuolization, improving the integrity of complex-III of the Mitochondrial Electron
Transport Chain (METC) after DOXO treatment [56] (Figure 1). Treatment with OL also
reduced the infarct size in normal and hypercholesterolemic rabbits [57]. Additionally,
OL protection was associated with a reduction in total cholesterol and triglyceride levels
in reperfused myocardium [57]. Furthermore, HT reduced the protein expression related
to ageing, the infarct size, and apoptosis in cardiomyocytes [58]. In tyrosol-treated rats
compared to non-treated animals, a reduced infarct size was observed, with a concomitant
improvement in the myocardial function [59]. In particular, OL was able to inhibit the my-
ocardial infarction size and reduce the levels of Creatine-Kinase MB isohenzyme (CK-MB)
and lactate dehydrogenase (LDH) in a model of myocardial ischemia-reperfusion in rats.
The mechanism of olea derivatives is still unknown. However, recent data showed that,
in myocardial I/R rats, OL modulated the ERK pathway and suppressed the induction of
p53, p-MEK, and p-ERK protein expression [60]. Cisplatin-induced acute renal injury was
attenuated by OL through the inhibition of p53 and ERK signalling in mice [61]. Moreover,
evidence exists that the cardioprotective effects of OLEX and HT are mainly exerted via en-
doplasmic reticulum (ER) stress prevention [62]. Indeed, the administration of HT prevents
ER-stress-induced apoptosis by inhibiting the mRNA and protein expression of GRP78 and
CHOP in hypoxia-induced H9c2 cells. On the other hand, pre-treatment with OLEX pre-
vents inflammation and reduces the infarct size, improving ejection fraction and shortening
fraction FS in isoproterenol-induced myocardial infarction in rats [62]. Finally, recent data
suggested that OL prevents oxidative stress directly scavenging O2- in AngII-mediated
human vascular progenitor cell (VPC) depletion. Furthermore, evidence has been collected
suggesting that OL exerts its protective effects via upregulation of the ERK1/2-Prdx1 and 2
and Akt/eNOS signalling pathway [63] (Figure 2). Therefore, derivatives of Olea Europea L.
appear to represent natural compounds able to exert a cardioprotective response acting on
pathways which lead to the impairment of cardiomyocytes.
3.4. Apple-Derived Natural SGLT2-Inhibitors
The principle phenolic-glucoside in apple trees is phlorizin, which is present in roots,
bark, shoots, and leaves [231]. It is a naturally competitive inhibitor of SGLT2, providing
the first insights into the potential efficacy of this compound [64]. Many effects of the
phlorizin-rich extract contribute to its potential use in treatments to ameliorate diabetes
and other metabolic disorders. In fact, it has been reported that apple juice and apple
extracts contain a total phenolic concentration of 11%–36% phlorizin, which could inhibit
oxLDL levels [65]. Additionally, in isolated coronary artery rings, the aglycon of phlorizin—
phloretin—produces endothelium-independent relaxation [66,67].
Many pre-clinical studies have found that phlorizin produces effects such as lower-
ing serum glucose and improving insulin-resistance [68–70]. In addition, with the scope
of observing the absorption of delayed intestinal glucose, in 1997, Japanese researchers
demonstrated an effect on the post-prandial rise of serum glucose after orally administering
phlorizin to mice [71]. Following these observations, investigators at Tanabe Seiyaku Co., a
Japanese pharmaceutical company, developed a phlorizin derivative; 3-(Benzo[b]furan-5-
yl)-2′,6′-dihydroxy-4′-methyl-propiophenone-2′-O-(6-O-methoxycarbonyl)-β-D- glucopyra-
noside (T-1095) [72]. In particular, it was demonstrated that the oral administration of T1095
leads to an improvement in hyperglycaemia and insulin resistance in the skeletal muscle of
streptozotocin (STZ)-induced diabetic rats [72]. In addition, data have also been provided
showing that T-1095 improves hyperglycaemia by suppressing the renal reabsorption of
glucose, possibly via inhibition of the expression of Na+-glucose cotransporters (SGLTs)
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and of the abnormal expression of GLUT2 in the kidney [73]. Therefore, due to the emerg-
ing evidence on the successful use of SGLT2 inhibitors in diabetic cardiomyopathy (see
Section 2.5), it is likely that the phlorizin-rich apple extract may represent a potential candi-
date for supplementation in diabetes-associated impairment of the cardiac performance.
3.5. Grape Seed Extract
The grape seed extract (GSE) represents a source of active ingredients which have
been suggested to have beneficial effects on many disease states, including cardiovascular
disorders; for a review, see [232]. Among the active ingredients found in GSE, proantho-
cyanidins (PCs) were found to be able to produce therapeutic, biological, pharmacological
and chemoprotective properties against free radicals and oxidative stress see [232]. In-
terestingly, grape seed PCs have shown cardioprotective effects through the modulation
of mitochondrial and lysosomal function [74]. In fact, in isoproterenol- treated rats, co-
treatment with PCs reduced the activities of lysosomal enzymes in the heart tissues and
increased respiratory chain enzymes and mitochondrial activity [74].
Many of the cardiovascular benefits attributed to GSE rich in PCs have been found
to be related to their antioxidant profile. Indeed, GSE exhibited dramatic concentration-
dependent antioxidant activity [75]. Additionally, in mice, the dose-dependent protective
ability of GSE was excellent against 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced
hepatic peroxidation, as well as DNA fragmentation, peritoneal macrophage activation, and
brain lipid peroxidation [76]. Moreover, in a primary culture of human oral keratinocytes,
GSPE demonstrated significant protection against DNA damage, oxidative stress induced
by smokeless tobacco, and apoptotic cell death [77]. Additionally, GSE was shown to
enhance the cytotoxic effects of idarubicin and 4-hydroxyperoxycyclophosphamide on
Chang liver cells [78] and exerted a direct cytotoxic effect on cultured human cancer
cells [79]. Finally, Bagchi [80] and Ray [81] reported that GSE also leads to significant
protection against chemotherapeutic drug-induced cytotoxicity in common liver cells via
the counteraction of both programmed and non-programmed cell death.
This was confirmed in cardiomyocytes [82]. Indeed, Sato et al. showed that GSE rich in
PCs reduced the apoptotic cell death of cardiomyocytes in ischemia/reperfusion-induced
damage, representing an effect driven by the activation of jnk-1 and c-jun [82]. Therefore,
GSE rich in PCs leads to an antioxidant and anti-apoptotic effect in failing myocardial cells
by means of antagonistic properties on ischaemia–reperfusion-induced activation of c-jun
and by modulating the pro-apoptotic gene JNK-1.
4. Conclusions and Future Perspectives
The use of nutritional support and nutraceutical supplementation in HF patients
has been suggested, over the last decades, on the basis of both pre-clinical and clinical
studies carried out worldwide. However, there are consistent controversies with regards to
defining the real contribution of nutraceutical interventions in the course of the disease and
their correct impact on approaching hospitalisation and death in patients undergoing HF.
Recent studies exploring pathophysiological mechanisms characterizing the early stages
of HF, mostly in the course of cardiometabolic disorders underlying impaired myocardial
dysfunction, have allowed the possible identification of a condition of “cardiomyocyte
frailty” in which oxidative stress and mitochondrial dysfunction seem to play a crucial role.
Under these conditions, protective mechanisms which include autophagic responses and
endogenous anti-oxidant enzyme overexpression are activated to antagonise the apoptotic
cell death of myocardial cells. This stage of the disease is accompanied by an alteration
in ER, calcium imbalance and an inappropriate regulation of MMPs, which have been
shown to increase the stiffness of the left ventricle, leading to diastolic dysfunction. At
this stage of the disease, based on their antioxidant and anti-apoptotic properties, several
plant extracts, characterised by the specific modulation of oxidative processes which
should occur at the early stages of cardiac dysfunction, are expected to play a role in
counteracting the development of HF. To this end, contribution to the mobilisation of
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stem cells could have a further beneficial effect in supporting the failing myocardium
at any stage of the disease. On the basis of this preliminary evidence, it is likely that a
due combination of plant extracts, well-characterised in terms of active ingredients, may
represent a potential resource to support endogenous compensatory mechanisms which
characterise the “frail myocardium” at the early stages in the development of HF. This
should be defined by means of multicentric clinical studies, randomised, double-blind and
placebo-controlled, to be carried out on a large number of subjects, in order to verify the
efficacy and safety profile of nutraceuticals. An assessment of their placement in therapy
according to the stages of the disease is also required to define their contribution to disease
progression, alongside conventional treatment assessed according to the international
guidelines. Finally, a regulatory intervention to better define the right management of
nutraceuticals in cardiovascular disease should increase their impact and credibility in
clinical practice.
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